Plunkett Research Online: Cadrenal Therapeutics Inc

CADRENAL THERAPEUTICS INC (CVKD:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tec.....



Cadrenal Therapeutics Inc
Ticker: CVKD
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 904 300-0701
Fax:
Address: 822 A1A North
Suite 306
Ponte Vedra, FL 32082 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Biotechnology
Biotechnology
Healthcare

Ranks not available
Contacts Description
Quang PhamCEO/Chairman of the Board/Director
Matthew SzotCFO/Chief Accounting Officer
See More
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tec.....See More See More

Auditor: WithumSmith+Brown, PC
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2023
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: